Dupilumab use for atopic dermatitis and other conditions was associated with an increased risk of incident psoriasis but not psoriatic arthritis.

Age at diagnosis, when treated as a continuous variable, appears to impact long-term remission outcomes among patients with JIA.

U.S. Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. signed off on the recommendation from an expert panel that recommended removing the mercury-based preservative from all influenza ...

Patients perceived physicians as less competent, trustworthy, and empathetic if they used AI in their practice.

Regardless of dose used, povorcitinib use for 24 weeks among patients with extensive nonsegmental vitiligo improved total and facial repigmentation.

A broad spectrum of systemic inflammatory manifestations defines VEXAS syndrome, with cutaneous, respiratory, and vascular involvement commonly reported.

The recurrence rates of curettage alone are comparable to that of curettage with electrodessication in patients with keratinocyte carcinoma.

The loved ones of those with cancer report an emotional burden, including concerns about life expectancy, course of treatment, and pain.

The FDA has appointed George Francis Tidmarsh, MD, PhD, to be the director of the Center for Drug Evaluation and Research.

The FDA has accepted for review the sNDA for deucravacitinib for the treatment of adults with active psoriatic arthritis.

Intraclass biologic switching had better short-term efficacy in psoriasis, but both intraclass and interclass switching were effective long-term.

The FDA has issued a CRL to Replimmune regarding the BLA for vusolimogene oderparepvec (RP1) in combination with nivolumab for advanced melanoma.